DK2608670T3 - Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning - Google Patents

Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning Download PDF

Info

Publication number
DK2608670T3
DK2608670T3 DK11820517.8T DK11820517T DK2608670T3 DK 2608670 T3 DK2608670 T3 DK 2608670T3 DK 11820517 T DK11820517 T DK 11820517T DK 2608670 T3 DK2608670 T3 DK 2608670T3
Authority
DK
Denmark
Prior art keywords
compound
use according
atypical
antipsychotic
treatment
Prior art date
Application number
DK11820517.8T
Other languages
English (en)
Inventor
Daniel Deaver
Mark Todtenkopf
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Application granted granted Critical
Publication of DK2608670T3 publication Critical patent/DK2608670T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (20)

1. Forbindelse med strukturen:
eller et farmaceutisk acceptabelt salt deraf, til anvendelse i en fremgangsmåde til reducering af antipsykotikum-induceret vægtstigning.
2. Sammensætning, der omfatter et atypisk antipsykotikum og en forbindelse med strukturen: eller et farmaceutisk acceptabelt salt deraf.
3. Sammensætning ifølge krav 2, hvor det atypiske antipsykotikum er valgt blandt olanzapin, clozapin, risperidon, quetiapin, aripiprazol, ziprasidon og farmaceutisk acceptable salte deraf.
4. Sammensætning ifølge krav 2 eller 3, hvor sammensætningen er i form af en oral tablet.
5. Forbindelse til anvendelse ifølge krav 1, hvor vægtstigningen er induceret af indgivelse af et atypisk antipsykotikum.
6. Forbindelse til anvendelse ifølge krav 5, hvor det atypiske antipsykotikum er valgt fra gruppen bestående af olanzapin, clozapin, risperidon, quetiapin, aripiprazol, ziprasidon og farmaceutisk acceptable salte deraf.
7. Forbindelse til anvendelse ifølge krav 6, hvor det atypiske antipsykotikum anvendes i behandlingen af skizofreni, bipolar sygdom, demens, akut mani, alvorlig depression og psykotisk agitation.
8. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 eller 5 til 7, hvor forbindelsen indgives i en daglig dosis på fra ca. 3 til ca. 30 mg om dagen.
9. Forbindelse til anvendelse ifølge krav 8, hvor forbindelsen indgives i en daglig dosis på fra ca. 3 til ca. 15 mg om dagen.
10. Forbindelse til anvendelse ifølge krav 9, hvor den daglige dosis er ca. 5 mg om dagen.
11. Forbindelse til anvendelse ifølge krav 9 eller krav 10, hvor den daglige dosis indgives peroralt.
12. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 5 til 11, hvor patienten har taget ca. 2, 3, 4, 5, 10, 15 eller 20 % kropsvægt på inden for en periode på en uge fra starten af behandlingen med atypisk antipsykotikum, inden for en periode på en uge under behandlingen med atypisk antipsykotikum, inden for en periode på en måned fra starten af behandlingen med atypisk antipsykotikum eller inden for en periode på en måned under behandlingen med atypisk antipsykotikum.
13. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 5 til 11, hvor patienten har taget ca. 2, 3, 4, 5, 10, 15 eller 20 % kropsvægt på inden for en periode på en uge umiddelbart forud for starten på indgivelsen af forbindelsen eller inden for en periode på en måned umiddelbart forud for starten på indgivelsen af forbindelsen.
14. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 5 til 11, hvor patienten inden for et års behandling med atypisk antipsykotikum har taget ca. 5, 10, 15, eller 20 % kropsvægt på.
15. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 5 til 11, hvor forbindelsen indgives forud for den daglige dosis af det atypiske antipsykotikum, eller hvor forbindelsen indgives efter den daglige dosis af atypisk antipsykotikum.
16. Forbindelse til anvendelse ifølge krav 1,hvor forbindelsen indgives til patienten forud for begyndelsen på den antipsykotikum-inducerede vægtstigning, eller hvor forbindelsen indgives i starten af patientens behandling med atypisk antipsykotikum.
17. Forbindelse med strukturen eller et farmaceutisk acceptabelt salt deraf, til anvendelse i en fremgangsmåde til dæmpning affødeindtaget eller en fremgangsmåde til reducering af ghrelin-niveauerne, hvor den forhøjede appetit eller de forhøjede ghrelin-niveauer er induceret af indgivelse af et atypisk antipsykotikum.
18. Forbindelse med strukturen
eller et farmaceutisk acceptabelt salt deraf, til anvendelse i en fremgangsmåde til reducering af ghrelin-niveauet i mavetarmkanalen.
19. Forbindelse til anvendelse ifølge krav 17 eller krav 18, hvor forbindelsen indgives i en daglig dosis på fra ca. 3 til ca. 30 mg om dagen, fortrinsvis i en daglig dosis på fra ca. 3 til ca. 15 mg om dagen.
20. Forbindelse til anvendelse ifølge krav 19, hvor den daglige dosis er ca. 5 mg om dagen.
DK11820517.8T 2010-08-23 2011-08-23 Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning DK2608670T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37612010P 2010-08-23 2010-08-23
PCT/US2011/048794 WO2012027359A1 (en) 2010-08-23 2011-08-23 Methods for treating antipsychotic-induced weight gain

Publications (1)

Publication Number Publication Date
DK2608670T3 true DK2608670T3 (da) 2019-02-11

Family

ID=45723770

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18198977.3T DK3446565T3 (da) 2010-08-23 2011-08-23 Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
DK11820517.8T DK2608670T3 (da) 2010-08-23 2011-08-23 Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18198977.3T DK3446565T3 (da) 2010-08-23 2011-08-23 Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning

Country Status (19)

Country Link
US (11) US8778960B2 (da)
EP (3) EP3446565B1 (da)
JP (1) JP5684388B2 (da)
AU (4) AU2011293502B2 (da)
CA (1) CA2807965C (da)
CY (1) CY1121128T1 (da)
DK (2) DK3446565T3 (da)
ES (2) ES2705726T3 (da)
FI (1) FI3446565T3 (da)
HR (2) HRP20240109T1 (da)
HU (2) HUE041981T2 (da)
LT (2) LT3446565T (da)
NZ (1) NZ606730A (da)
PL (2) PL3446565T3 (da)
PT (2) PT3446565T (da)
RS (2) RS65091B1 (da)
SI (2) SI2608670T1 (da)
TR (1) TR201900097T4 (da)
WO (1) WO2012027359A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2445502T (pt) * 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
RS58894B1 (sr) 2009-12-04 2019-08-30 Alkermes Pharma Ireland Ltd Derivati morfinana za lečenje predoziranja lekom
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US20210220298A1 (en) * 2018-06-29 2021-07-22 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
WO2022101444A1 (en) * 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2023105103A1 (es) 2022-06-17 2023-06-15 Mesoestetic Pharma Group, S.L Composición cosmética sinérgica despigmentante de la piel

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
BE634402A (fr) 1962-07-02 1964-01-02 British Drug Houses Ltd Dérivés de l'hydrophénanthrène et leurs procédés de préparation
GB981046A (en) 1962-07-02 1965-01-20 British Drug Houses Ltd Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH581624A5 (da) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
JPH05231100A (ja) 1992-02-25 1993-09-07 Hazama Gumi Ltd トンネル用通気仕切り
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
PT729353E (pt) 1993-11-19 2002-07-31 Alkermes Inc Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997025331A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1210084A4 (en) 1999-08-13 2002-11-13 Southern Res Inst PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
CA2392362A1 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
DE60109960T2 (de) 2000-10-31 2006-02-16 Rensselaer Polytechnic Institute 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
EP1485051B1 (en) 2002-03-20 2008-05-07 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
ATE308522T1 (de) 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
US7271173B2 (en) 2002-11-18 2007-09-18 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
EP1737454A4 (en) 2004-04-22 2007-08-08 Mor Research Applic Ltd METHOD OF MANAGING FOOD RECOVERY
WO2005113486A1 (en) 2004-05-14 2005-12-01 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
CA2587074C (en) * 2004-11-05 2012-09-04 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
CA2615774C (en) 2005-07-21 2014-12-09 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
WO2007089934A2 (en) 2006-02-01 2007-08-09 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
RU2009112685A (ru) 2006-09-20 2010-10-27 Маллинкродт Инк. (Us) Получение замещенных морфинан-6-онов и их солей и промежуточных соединений
WO2008048711A1 (en) 2006-10-17 2008-04-24 Penick Corporation Process for preparing oxymorphone
MX2009005461A (es) 2006-11-22 2009-08-28 Progenics Pharm Inc N-oxidos de analogos de 4,5-epoxi-morfinano.
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010527374A (ja) 2007-05-16 2010-08-12 レンセラール ポリテクニック インスティチュート 縮合環複素環オピオイド
WO2009009083A1 (en) 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
KR101519682B1 (ko) 2007-08-09 2015-05-19 렌슬러 폴리테크닉 인스티튜트 4급 오피오이드 카르복스아미드
ES2671897T3 (es) 2008-02-14 2018-06-11 Alkermes, Inc. Compuestos opioides selectivos
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
AU2009274147B2 (en) 2008-07-21 2014-09-04 Rensselaer Polytechnic Institute Large substituent, non-phenolic amine opioids
JP5555890B2 (ja) 2009-03-19 2014-07-23 アルカーメス ファーマ アイルランド リミテッド 高い経口バイオアベイラビリティを有するモルフィナン誘導体
WO2010141666A2 (en) 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
RS58894B1 (sr) 2009-12-04 2019-08-30 Alkermes Pharma Ireland Ltd Derivati morfinana za lečenje predoziranja lekom
EP2550253B9 (en) 2010-03-22 2016-09-21 Rensselaer Polytechnic Institute Morphinane derivatives containing a carboxamide group as opioid receptor ligands
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
US8624030B2 (en) 2010-08-04 2014-01-07 Mallinckrodt Llc N-demethylation of 6-keto morphinans
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
WO2012088494A1 (en) 2010-12-23 2012-06-28 Pheonix Pharmalabs, Inc. Novel morphinans useful as analgesics
MX2014007042A (es) 2011-12-15 2015-01-22 Alkermes Pharma Ireland Ltd Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use

Also Published As

Publication number Publication date
US11241425B2 (en) 2022-02-08
US20120077800A1 (en) 2012-03-29
HRP20190169T1 (hr) 2019-03-22
US9126977B2 (en) 2015-09-08
EP4306164A2 (en) 2024-01-17
RS58312B1 (sr) 2019-03-29
US20210038594A1 (en) 2021-02-11
EP2608670B1 (en) 2018-10-31
US20170119757A1 (en) 2017-05-04
US20180271855A1 (en) 2018-09-27
PT3446565T (pt) 2024-01-29
SI3446565T1 (sl) 2024-03-29
LT3446565T (lt) 2024-01-10
EP4306164A3 (en) 2024-03-20
AU2011293502B2 (en) 2015-03-19
EP2608670A1 (en) 2013-07-03
JP5684388B2 (ja) 2015-03-11
DK3446565T3 (da) 2024-01-22
US11793805B2 (en) 2023-10-24
US20240293394A1 (en) 2024-09-05
ES2705726T3 (es) 2019-03-26
US9943514B2 (en) 2018-04-17
AU2018202410A1 (en) 2018-04-26
CA2807965C (en) 2016-03-15
AU2017200396B2 (en) 2018-04-19
US10300054B2 (en) 2019-05-28
TR201900097T4 (tr) 2019-02-21
AU2018202410B2 (en) 2019-02-28
PL2608670T3 (pl) 2019-05-31
HUE065427T2 (hu) 2024-05-28
PL3446565T3 (pl) 2024-04-02
US8778960B2 (en) 2014-07-15
US10716785B2 (en) 2020-07-21
LT2608670T (lt) 2019-01-25
PT2608670T (pt) 2019-02-01
US11351166B2 (en) 2022-06-07
FI3446565T3 (fi) 2024-01-30
AU2015201907A1 (en) 2015-05-07
RS65091B1 (sr) 2024-02-29
EP3446565B1 (en) 2023-11-01
HRP20240109T1 (hr) 2024-03-29
EP3446565A1 (en) 2019-02-27
AU2015201907B2 (en) 2016-12-22
ES2969625T3 (es) 2024-05-21
US20140349999A1 (en) 2014-11-27
SI2608670T1 (sl) 2019-04-30
EP2608670A4 (en) 2014-05-07
WO2012027359A1 (en) 2012-03-01
US20190307742A1 (en) 2019-10-10
US9517235B2 (en) 2016-12-13
US20210046065A1 (en) 2021-02-18
JP2013536239A (ja) 2013-09-19
NZ606730A (en) 2015-05-29
CY1121128T1 (el) 2019-12-11
US11185541B2 (en) 2021-11-30
CA2807965A1 (en) 2012-03-01
AU2011293502A1 (en) 2013-02-28
AU2017200396A1 (en) 2017-02-09
HUE041981T2 (hu) 2019-06-28
US20160051538A1 (en) 2016-02-25
US20220280502A1 (en) 2022-09-08
US20210015812A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US11793805B2 (en) Methods for treating antipsychotic-induced weight gain
EP1238676B1 (en) Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis
JP2010535220A (ja) 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物
CN107007603A (zh) 使用环酰胺衍生物治疗σ受体介导的病症的方法